FUSID

Pajjiż: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

FUROSEMIDE

Disponibbli minn:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Kodiċi ATC:

C03CA01

Għamla farmaċewtika:

TABLETS

Kompożizzjoni:

FUROSEMIDE 40 MG

Rotta amministrattiva:

PER OS

Tip ta 'preskrizzjoni:

Required

Manifatturat minn:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Grupp terapewtiku:

FUROSEMIDE

Żona terapewtika:

FUROSEMIDE

Indikazzjonijiet terapewtiċi:

Edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Adjunctive therapy in acute pulmonary edema. Treatment of hypertension.

Data ta 'l-awtorizzazzjoni:

2011-06-30

Fuljett ta 'informazzjoni

_6_
_6_
_._
_._
!
Furosemide 40 mg
_ _
Lactose, microcrystalline cellulose, starch, crospovidone, povidone,
magnesium stearate,
colloidal silicon dioxide, propylparaben, butylparaben.
!
"
"
#
"
#
"
#
"
#
"
"
#
"
!
"
#
$
%
#
$
%
"
#
"
&
"
#
#
$
%
$
%
"
#
$
$
"
$
'
%
#
#
$
(
%
"
#
!
'
"
"
"
#
"
"
#
"
"
#
$
%
%
"
#
"
$
%
$
%
$
%
$
%
$
%
$
%
$
%
$
!
%
$
%
$
%
$
%
!
$
ACE
%
%
$
%
$
%
$
%
$
%
2
(liquorice)
$
%
$
%
3
'
#
$
#
%
$
%
#
#
"
#
"
!
"
"
"
#
$
%
'
"
!
!
"
"
#
#
'
$
%
)
*******************************************
*
"
*
*******************************************
"
&
!
#
"
#
#
"
)
"
+
$
%
$
!
'
$
$
(
"
)
#
"
#
"
#
25 C
#
"
)
"
!
"
)
*
020 20 20472 00
+
020 20 20472 11
,-.
/-, ,

Karatteristiċi tal-prodott

1
Fusid-tablets_SPC_Notification-worsing_12-2020_NS
SUMMARY OF PRODUCT CHARACTERISTICS
FUSID TABLETS
Tablets
1.
NAME OF THE MEDICINAL PRODUCT
Fusid tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 40 mg Furosemide
For the full list of excipients, see section Error! Reference source
not found..
3.
PHARMACEUTICAL FORM
White, round flat tablet, engraved "TEVA" on one side and bisected on
the other side of the
tablets.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
If gastrointestinal absorption is impaired or oral administration is
not practical for any reason,
and for patients in emergency clinical situations, Fusid is indicated
by the intravenous or the
intra-muscular route. Parenteral use should be replaced with oral
Fusid as soon as practical.
-
Treatment of edema associated with congestive heart failure, cirrhosis
of the liver and renal
disease, including the nephrotic syndrome.
-
Adjunctive therapy in acute pulmonary edema.
-
Treatment of hypertension.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
_Posology _
Since furosemide is a potent diuretic which, if given in excessive
amounts, can lead to profound
diuresis with water and electrolyte depletion, careful medical
supervision is required. Dosage
should be adjusted to the individual needs of each patient.
_Adults _
_Edema:_ The usual initial dose is 20-80 mg/day administered as a
single dose. Usually, prompt
diuresis ensues. Depending on the response, a second dose should be
administered 6-8 hours
later. If the diuretic response is unsatisfactory, the dose should be
increased by increments of 20
or 40 mg, no sooner than 6-8 hours after previous dose, until the
desired diuretic effect has been
obtained. This individually-determined dose should then be
administered 1-2 times a day. In
patients with severe edema, dosage may be titrated up to 600 mg/day.
Mobilization of edema may be most efficiently and safely accomplished
with an intermittent
dosage schedule. Furosemide should be administered on 2-4 consecutive
days, each week.
With do